GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » EV-to-FCF

IGC Pharma (FRA:IGS1) EV-to-FCF : -5.84 (As of Dec. 15, 2024)


View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, IGC Pharma's Enterprise Value is €29.42 Mil. IGC Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-5.04 Mil. Therefore, IGC Pharma's EV-to-FCF for today is -5.84.

The historical rank and industry rank for IGC Pharma's EV-to-FCF or its related term are showing as below:

FRA:IGS1' s EV-to-FCF Range Over the Past 10 Years
Min: -93.45   Med: -4.19   Max: 40.15
Current: -5.62

During the past 13 years, the highest EV-to-FCF of IGC Pharma was 40.15. The lowest was -93.45. And the median was -4.19.

FRA:IGS1's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs FRA:IGS1: -5.62

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-15), IGC Pharma's stock price is €0.368. IGC Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.166. Therefore, IGC Pharma's PE Ratio (TTM) for today is At Loss.


IGC Pharma EV-to-FCF Historical Data

The historical data trend for IGC Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma EV-to-FCF Chart

IGC Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.57 -5.81 -4.69 -1.98 -4.52

IGC Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.92 -2.57 -4.52 -5.15 -5.74

Competitive Comparison of IGC Pharma's EV-to-FCF

For the Biotechnology subindustry, IGC Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGC Pharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where IGC Pharma's EV-to-FCF falls into.



IGC Pharma EV-to-FCF Calculation

IGC Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=29.423/-5.038
=-5.84

IGC Pharma's current Enterprise Value is €29.42 Mil.
IGC Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IGC Pharma  (FRA:IGS1) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

IGC Pharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.368/-0.166
=At Loss

IGC Pharma's share price for today is €0.368.
IGC Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.166.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


IGC Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of IGC Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


IGC Pharma Business Description

Traded in Other Exchanges
Address
10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma Headlines

No Headlines